质子泵抑制剂可导致肾衰竭?

2015-04-21 小闪 cmt

研究发现,老年患者服用质子泵抑制剂,一种治疗胃灼热和反酸一种常见的药,导致肾衰竭住院率的可能性是未服用者的两倍。虽然副作用是极其罕见的,但是相关性是令人担忧的,因为每年数百万人服用这些处方药和非处方药的销售的药物,包括奥美拉唑,兰索拉唑和奥美拉唑口服混悬液。“一般来说,这些药物耐受性很好,服用这些药物的绝大多数患者不会发展(肾功能衰竭)或其他严重的问题,”研究的首席作者Tony Antoniou,

研究发现,老年患者服用质子泵抑制剂,一种治疗胃灼热和反酸一种常见的药,导致肾衰竭住院率的可能性是未服用者的两倍。

虽然副作用是极其罕见的,但是相关性是令人担忧的,因为每年数百万人服用这些处方药和非处方药的销售的药物,包括奥美拉唑,兰索拉唑和奥美拉唑口服混悬液。

“一般来说,这些药物耐受性很好,服用这些药物的绝大多数患者不会发展(肾功能衰竭)或其他严重的问题,”研究的首席作者Tony Antoniou,多伦多圣迈克尔的医院临床评估科学研究所的研究人员说,“但是药物应在尽可能短的时间内使用。”

Antoniou博士及其同事研究了在安大略湖2002~2011年之间服用质子泵抑制剂的290000名66岁以上的老人,以及与其数量相当的没有服用此药的人群。

研究人员观察,在从开始服药的120天内,有多少人因患急性肾损伤住院,并与未服用药物组做比较。

研究人员排除了过去曾经服用这些药的人,也排除了在过去的五年中曾诊断肾功能衰竭的人,如HIV和狼疮疾病。而且,在过去四个月研究人员禁止这些人使用抗生素,因为感染或服用抗感染的药物可引起肾衰竭。

发生急性肾损伤有1787人,低于研究总人数的1%。服用质子泵抑制剂的人群住院率为每年13.49/1000人,没有服用药物的住院率为5.46/1000,此研究结果于2015年4月16日在线发表在CMAJ。

“基于这一研究,我不会限制的质子泵抑制剂使用;整体风险(肾功能衰竭)在研究人群中仍然很低,质子泵抑制剂和肾损伤的关联仍然只是一个相关性,”巴尔的摩的霍普金斯医院的胃肠病学家,John O'Brian Clarke博士说。

“这些药物所有可能的副作用,不是肾衰竭,是骨质疏松症”,没有参与这项研究的Clarke表示,“还有一种风险,人们不能吸收某些维生素和矿物质,如镁,铁,维生素B12和钙。”

“这项研究表明,质子泵抑制剂的使用不是没有风险的,” Clarke说,“临床医生应该对那些真正需要的质子泵抑制剂治疗的患者严格使用这些药物,寻找最小剂量及治疗进行必需的时间。”

某些患者可以服用抗酸药缓解胃灼热症状,质子泵抑制剂可以用在有更加严重临床症状的患者上,加利福尼亚大学戴维Geffen医学院George Sachs博士,在一封电子邮件中说。

“对胃食管反流病的患者,这些药物可以防止致命的食管癌的发展”,没有参与这项研究Sachs说。

“患者应定期检测质子泵抑制剂是否是必要的”,Antoniou说。

“在许多情况下,生活方式的改变(如避免辛辣食品,减肥)可能是必需的,”他说。

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1667295, encodeId=7c3a166e295d1, content=<a href='/topic/show?id=03ab923565b' target=_blank style='color:#2F92EE;'>#质子泵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92356, encryptionId=03ab923565b, topicName=质子泵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=761326143554, createdName=shenxlcyp, createdTime=Mon Jan 04 21:55:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28012, encodeId=cf5928012d7, content=厉害啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acd01628312, createdName=1dd82894m82(暂无匿称), createdTime=Wed Jun 17 23:25:00 CST 2015, time=2015-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25456, encodeId=787b2545687, content=这么厉害?, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d231626576, createdName=jjzouyan, createdTime=Sun May 31 10:43:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851238, encodeId=08e81851238f0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jan 28 12:55:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22173, encodeId=1074221e3f1, content=有待观察, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cad31998, createdName=dwtouxx, createdTime=Tue Apr 28 11:38:00 CST 2015, time=2015-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21732, encodeId=9cde21e321f, content=不知道, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Thu Apr 23 10:37:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299226, encodeId=ca121299226c8, content=<a href='/topic/show?id=e7e882e50df' target=_blank style='color:#2F92EE;'>#肾衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82750, encryptionId=e7e882e50df, topicName=肾衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Thu Apr 23 07:55:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21639, encodeId=455221639e2, content=有没有对比过两组患者基线时合并症的差异,服用PPI的人,也许是因为其他疾病的胃肠道表现,或许是服用其他药物后的胃肠道不适,如果基线没有可比性,这个结论也没有意义。最近怎么对PPI有种妖魔化的倾向了?, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=sumer, createdTime=Tue Apr 21 22:55:00 CST 2015, time=2015-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21624, encodeId=30ae2162468, content=不会吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Tue Apr 21 19:24:00 CST 2015, time=2015-04-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1667295, encodeId=7c3a166e295d1, content=<a href='/topic/show?id=03ab923565b' target=_blank style='color:#2F92EE;'>#质子泵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92356, encryptionId=03ab923565b, topicName=质子泵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=761326143554, createdName=shenxlcyp, createdTime=Mon Jan 04 21:55:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28012, encodeId=cf5928012d7, content=厉害啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acd01628312, createdName=1dd82894m82(暂无匿称), createdTime=Wed Jun 17 23:25:00 CST 2015, time=2015-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25456, encodeId=787b2545687, content=这么厉害?, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d231626576, createdName=jjzouyan, createdTime=Sun May 31 10:43:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851238, encodeId=08e81851238f0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jan 28 12:55:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22173, encodeId=1074221e3f1, content=有待观察, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cad31998, createdName=dwtouxx, createdTime=Tue Apr 28 11:38:00 CST 2015, time=2015-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21732, encodeId=9cde21e321f, content=不知道, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Thu Apr 23 10:37:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299226, encodeId=ca121299226c8, content=<a href='/topic/show?id=e7e882e50df' target=_blank style='color:#2F92EE;'>#肾衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82750, encryptionId=e7e882e50df, topicName=肾衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Thu Apr 23 07:55:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21639, encodeId=455221639e2, content=有没有对比过两组患者基线时合并症的差异,服用PPI的人,也许是因为其他疾病的胃肠道表现,或许是服用其他药物后的胃肠道不适,如果基线没有可比性,这个结论也没有意义。最近怎么对PPI有种妖魔化的倾向了?, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=sumer, createdTime=Tue Apr 21 22:55:00 CST 2015, time=2015-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21624, encodeId=30ae2162468, content=不会吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Tue Apr 21 19:24:00 CST 2015, time=2015-04-21, status=1, ipAttribution=)]
    2015-06-17 1dd82894m82(暂无匿称)

    厉害啊!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1667295, encodeId=7c3a166e295d1, content=<a href='/topic/show?id=03ab923565b' target=_blank style='color:#2F92EE;'>#质子泵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92356, encryptionId=03ab923565b, topicName=质子泵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=761326143554, createdName=shenxlcyp, createdTime=Mon Jan 04 21:55:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28012, encodeId=cf5928012d7, content=厉害啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acd01628312, createdName=1dd82894m82(暂无匿称), createdTime=Wed Jun 17 23:25:00 CST 2015, time=2015-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25456, encodeId=787b2545687, content=这么厉害?, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d231626576, createdName=jjzouyan, createdTime=Sun May 31 10:43:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851238, encodeId=08e81851238f0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jan 28 12:55:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22173, encodeId=1074221e3f1, content=有待观察, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cad31998, createdName=dwtouxx, createdTime=Tue Apr 28 11:38:00 CST 2015, time=2015-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21732, encodeId=9cde21e321f, content=不知道, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Thu Apr 23 10:37:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299226, encodeId=ca121299226c8, content=<a href='/topic/show?id=e7e882e50df' target=_blank style='color:#2F92EE;'>#肾衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82750, encryptionId=e7e882e50df, topicName=肾衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Thu Apr 23 07:55:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21639, encodeId=455221639e2, content=有没有对比过两组患者基线时合并症的差异,服用PPI的人,也许是因为其他疾病的胃肠道表现,或许是服用其他药物后的胃肠道不适,如果基线没有可比性,这个结论也没有意义。最近怎么对PPI有种妖魔化的倾向了?, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=sumer, createdTime=Tue Apr 21 22:55:00 CST 2015, time=2015-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21624, encodeId=30ae2162468, content=不会吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Tue Apr 21 19:24:00 CST 2015, time=2015-04-21, status=1, ipAttribution=)]
    2015-05-31 jjzouyan

    这么厉害?

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1667295, encodeId=7c3a166e295d1, content=<a href='/topic/show?id=03ab923565b' target=_blank style='color:#2F92EE;'>#质子泵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92356, encryptionId=03ab923565b, topicName=质子泵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=761326143554, createdName=shenxlcyp, createdTime=Mon Jan 04 21:55:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28012, encodeId=cf5928012d7, content=厉害啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acd01628312, createdName=1dd82894m82(暂无匿称), createdTime=Wed Jun 17 23:25:00 CST 2015, time=2015-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25456, encodeId=787b2545687, content=这么厉害?, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d231626576, createdName=jjzouyan, createdTime=Sun May 31 10:43:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851238, encodeId=08e81851238f0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jan 28 12:55:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22173, encodeId=1074221e3f1, content=有待观察, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cad31998, createdName=dwtouxx, createdTime=Tue Apr 28 11:38:00 CST 2015, time=2015-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21732, encodeId=9cde21e321f, content=不知道, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Thu Apr 23 10:37:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299226, encodeId=ca121299226c8, content=<a href='/topic/show?id=e7e882e50df' target=_blank style='color:#2F92EE;'>#肾衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82750, encryptionId=e7e882e50df, topicName=肾衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Thu Apr 23 07:55:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21639, encodeId=455221639e2, content=有没有对比过两组患者基线时合并症的差异,服用PPI的人,也许是因为其他疾病的胃肠道表现,或许是服用其他药物后的胃肠道不适,如果基线没有可比性,这个结论也没有意义。最近怎么对PPI有种妖魔化的倾向了?, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=sumer, createdTime=Tue Apr 21 22:55:00 CST 2015, time=2015-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21624, encodeId=30ae2162468, content=不会吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Tue Apr 21 19:24:00 CST 2015, time=2015-04-21, status=1, ipAttribution=)]
    2016-01-28 jklm09
  5. [GetPortalCommentsPageByObjectIdResponse(id=1667295, encodeId=7c3a166e295d1, content=<a href='/topic/show?id=03ab923565b' target=_blank style='color:#2F92EE;'>#质子泵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92356, encryptionId=03ab923565b, topicName=质子泵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=761326143554, createdName=shenxlcyp, createdTime=Mon Jan 04 21:55:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28012, encodeId=cf5928012d7, content=厉害啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acd01628312, createdName=1dd82894m82(暂无匿称), createdTime=Wed Jun 17 23:25:00 CST 2015, time=2015-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25456, encodeId=787b2545687, content=这么厉害?, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d231626576, createdName=jjzouyan, createdTime=Sun May 31 10:43:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851238, encodeId=08e81851238f0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jan 28 12:55:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22173, encodeId=1074221e3f1, content=有待观察, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cad31998, createdName=dwtouxx, createdTime=Tue Apr 28 11:38:00 CST 2015, time=2015-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21732, encodeId=9cde21e321f, content=不知道, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Thu Apr 23 10:37:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299226, encodeId=ca121299226c8, content=<a href='/topic/show?id=e7e882e50df' target=_blank style='color:#2F92EE;'>#肾衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82750, encryptionId=e7e882e50df, topicName=肾衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Thu Apr 23 07:55:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21639, encodeId=455221639e2, content=有没有对比过两组患者基线时合并症的差异,服用PPI的人,也许是因为其他疾病的胃肠道表现,或许是服用其他药物后的胃肠道不适,如果基线没有可比性,这个结论也没有意义。最近怎么对PPI有种妖魔化的倾向了?, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=sumer, createdTime=Tue Apr 21 22:55:00 CST 2015, time=2015-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21624, encodeId=30ae2162468, content=不会吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Tue Apr 21 19:24:00 CST 2015, time=2015-04-21, status=1, ipAttribution=)]
    2015-04-28 dwtouxx

    有待观察

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1667295, encodeId=7c3a166e295d1, content=<a href='/topic/show?id=03ab923565b' target=_blank style='color:#2F92EE;'>#质子泵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92356, encryptionId=03ab923565b, topicName=质子泵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=761326143554, createdName=shenxlcyp, createdTime=Mon Jan 04 21:55:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28012, encodeId=cf5928012d7, content=厉害啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acd01628312, createdName=1dd82894m82(暂无匿称), createdTime=Wed Jun 17 23:25:00 CST 2015, time=2015-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25456, encodeId=787b2545687, content=这么厉害?, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d231626576, createdName=jjzouyan, createdTime=Sun May 31 10:43:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851238, encodeId=08e81851238f0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jan 28 12:55:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22173, encodeId=1074221e3f1, content=有待观察, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cad31998, createdName=dwtouxx, createdTime=Tue Apr 28 11:38:00 CST 2015, time=2015-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21732, encodeId=9cde21e321f, content=不知道, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Thu Apr 23 10:37:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299226, encodeId=ca121299226c8, content=<a href='/topic/show?id=e7e882e50df' target=_blank style='color:#2F92EE;'>#肾衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82750, encryptionId=e7e882e50df, topicName=肾衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Thu Apr 23 07:55:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21639, encodeId=455221639e2, content=有没有对比过两组患者基线时合并症的差异,服用PPI的人,也许是因为其他疾病的胃肠道表现,或许是服用其他药物后的胃肠道不适,如果基线没有可比性,这个结论也没有意义。最近怎么对PPI有种妖魔化的倾向了?, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=sumer, createdTime=Tue Apr 21 22:55:00 CST 2015, time=2015-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21624, encodeId=30ae2162468, content=不会吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Tue Apr 21 19:24:00 CST 2015, time=2015-04-21, status=1, ipAttribution=)]
    2015-04-23 hbwang006

    不知道

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1667295, encodeId=7c3a166e295d1, content=<a href='/topic/show?id=03ab923565b' target=_blank style='color:#2F92EE;'>#质子泵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92356, encryptionId=03ab923565b, topicName=质子泵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=761326143554, createdName=shenxlcyp, createdTime=Mon Jan 04 21:55:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28012, encodeId=cf5928012d7, content=厉害啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acd01628312, createdName=1dd82894m82(暂无匿称), createdTime=Wed Jun 17 23:25:00 CST 2015, time=2015-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25456, encodeId=787b2545687, content=这么厉害?, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d231626576, createdName=jjzouyan, createdTime=Sun May 31 10:43:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851238, encodeId=08e81851238f0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jan 28 12:55:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22173, encodeId=1074221e3f1, content=有待观察, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cad31998, createdName=dwtouxx, createdTime=Tue Apr 28 11:38:00 CST 2015, time=2015-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21732, encodeId=9cde21e321f, content=不知道, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Thu Apr 23 10:37:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299226, encodeId=ca121299226c8, content=<a href='/topic/show?id=e7e882e50df' target=_blank style='color:#2F92EE;'>#肾衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82750, encryptionId=e7e882e50df, topicName=肾衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Thu Apr 23 07:55:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21639, encodeId=455221639e2, content=有没有对比过两组患者基线时合并症的差异,服用PPI的人,也许是因为其他疾病的胃肠道表现,或许是服用其他药物后的胃肠道不适,如果基线没有可比性,这个结论也没有意义。最近怎么对PPI有种妖魔化的倾向了?, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=sumer, createdTime=Tue Apr 21 22:55:00 CST 2015, time=2015-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21624, encodeId=30ae2162468, content=不会吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Tue Apr 21 19:24:00 CST 2015, time=2015-04-21, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1667295, encodeId=7c3a166e295d1, content=<a href='/topic/show?id=03ab923565b' target=_blank style='color:#2F92EE;'>#质子泵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92356, encryptionId=03ab923565b, topicName=质子泵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=761326143554, createdName=shenxlcyp, createdTime=Mon Jan 04 21:55:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28012, encodeId=cf5928012d7, content=厉害啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acd01628312, createdName=1dd82894m82(暂无匿称), createdTime=Wed Jun 17 23:25:00 CST 2015, time=2015-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25456, encodeId=787b2545687, content=这么厉害?, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d231626576, createdName=jjzouyan, createdTime=Sun May 31 10:43:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851238, encodeId=08e81851238f0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jan 28 12:55:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22173, encodeId=1074221e3f1, content=有待观察, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cad31998, createdName=dwtouxx, createdTime=Tue Apr 28 11:38:00 CST 2015, time=2015-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21732, encodeId=9cde21e321f, content=不知道, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Thu Apr 23 10:37:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299226, encodeId=ca121299226c8, content=<a href='/topic/show?id=e7e882e50df' target=_blank style='color:#2F92EE;'>#肾衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82750, encryptionId=e7e882e50df, topicName=肾衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Thu Apr 23 07:55:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21639, encodeId=455221639e2, content=有没有对比过两组患者基线时合并症的差异,服用PPI的人,也许是因为其他疾病的胃肠道表现,或许是服用其他药物后的胃肠道不适,如果基线没有可比性,这个结论也没有意义。最近怎么对PPI有种妖魔化的倾向了?, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=sumer, createdTime=Tue Apr 21 22:55:00 CST 2015, time=2015-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21624, encodeId=30ae2162468, content=不会吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Tue Apr 21 19:24:00 CST 2015, time=2015-04-21, status=1, ipAttribution=)]
    2015-04-21 sumer

    有没有对比过两组患者基线时合并症的差异,服用PPI的人,也许是因为其他疾病的胃肠道表现,或许是服用其他药物后的胃肠道不适,如果基线没有可比性,这个结论也没有意义。最近怎么对PPI有种妖魔化的倾向了?

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1667295, encodeId=7c3a166e295d1, content=<a href='/topic/show?id=03ab923565b' target=_blank style='color:#2F92EE;'>#质子泵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92356, encryptionId=03ab923565b, topicName=质子泵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=761326143554, createdName=shenxlcyp, createdTime=Mon Jan 04 21:55:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28012, encodeId=cf5928012d7, content=厉害啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acd01628312, createdName=1dd82894m82(暂无匿称), createdTime=Wed Jun 17 23:25:00 CST 2015, time=2015-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25456, encodeId=787b2545687, content=这么厉害?, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d231626576, createdName=jjzouyan, createdTime=Sun May 31 10:43:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851238, encodeId=08e81851238f0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jan 28 12:55:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22173, encodeId=1074221e3f1, content=有待观察, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cad31998, createdName=dwtouxx, createdTime=Tue Apr 28 11:38:00 CST 2015, time=2015-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21732, encodeId=9cde21e321f, content=不知道, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Thu Apr 23 10:37:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299226, encodeId=ca121299226c8, content=<a href='/topic/show?id=e7e882e50df' target=_blank style='color:#2F92EE;'>#肾衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82750, encryptionId=e7e882e50df, topicName=肾衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Thu Apr 23 07:55:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21639, encodeId=455221639e2, content=有没有对比过两组患者基线时合并症的差异,服用PPI的人,也许是因为其他疾病的胃肠道表现,或许是服用其他药物后的胃肠道不适,如果基线没有可比性,这个结论也没有意义。最近怎么对PPI有种妖魔化的倾向了?, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=sumer, createdTime=Tue Apr 21 22:55:00 CST 2015, time=2015-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21624, encodeId=30ae2162468, content=不会吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Tue Apr 21 19:24:00 CST 2015, time=2015-04-21, status=1, ipAttribution=)]
    2015-04-21 hbwang006

    不会吧

    0

相关资讯

Gut:胃食管反流病相关研究进展

随着肥胖造成的问题呈指数性的增长,世界范围内胃肠反流性疾病及其并发症的发病率也明显增加。其中人们特别关注的是中心性肥胖和包括食管腺癌在内的胃肠反流性疾病相关并发症之间的关系。 因对胃肠反流性疾病的流行病学和病理生理学了解的深入,早期认为胃食管反流是因为一个主要机制引起的发病率增加,但目前人们越来越接受胃肠反流病是一个多因素疾病。其诱发因素例如肥胖、年龄、遗传因素、妊娠以及创伤等同样可能在胃食

NICE指南:儿童胃食管反流病

胃食管反流是一种正常的生理现象,但是当其可致严重症状而需治疗或引起并发症时则称为胃食管反流病(GORD)。在婴幼儿和儿童中,由于存在各种潜在症状且缺乏简单可靠、能广泛使用的诊断性检测方法,故难以鉴别生理性胃食管反流和病理性胃食管反流病,这会导致极大的临床实践差异。 该病可影响儿童,包括早产和足月新生儿、健康婴幼儿和儿童及确定有明确危险因素的患儿,如膈疝修补术后、其他先天性畸形、严重的

不可忽视的幽门螺杆菌!!!

胃病细菌学的相关研究,长期以来一直是一个被忽视的领域。1983年澳大利亚学者Marshall和Warren从慢性胃炎患者的胃粘膜活检标本中首次分离出幽门螺杆菌(Helicobacter pylori, Hp)。此后不久该发现即在国际医学界引起了巨大轰动,它对消化病学、特别是胃十二指肠病学的发展起了极大的推动作用,可以说具有里程碑式的价值。鉴于该发现的重要价值,2005年度诺贝尔生理学或医学

Gut:PPIs不增加患者发生社区获得性肺炎的风险

质子泵抑制剂(PPIs)的过度使用及其潜在风险性正逐渐引起广泛关注,其焦点之一是PPIs引发肺炎的风险。相关假说认为胃和食管内细菌的过度生长可使患者将其吸入肺中的可能性增加。【原文下载】 尽管之前有观察性研究显示,PPIs的应用与社区获得性肺炎相关,但这些研究存在一定的限制性。比如观察对象包括胃食管反流(GERD)患者,而GERD本身就是肺炎的独立危险因素。为减少上述偏倚造成的影响,来自加拿

2014中国GERD共识意见发布

自2007年我国发布胃食管反流病(GERD)治疗共识意见至今的7年时间内,GERD诊疗有了长足的发展,国内外亦有很多高质量临床研究问世。为推动GERD规范化诊疗的普及、提高临床医生的GERD诊疗水平,中华医学会消化病学分会发起,2014年《中国胃食管反流病共识意见》(以下简称:共识意见)已于近日完稿,并在北京隆重召开发布解读会。 2014中国GERD共识意见发布暨解读会启动仪式